Canada · Delayed Price · Currency is CAD Biocure Technology Statistics
Total Valuation
CSE:CURE.X has a market cap or net worth of CAD 606,210. The enterprise value is 612,780.
| Market Cap | 606,210 |
| Enterprise Value | 612,780 |
Important Dates
The last earnings date was Wednesday, November 26, 2025.
| Earnings Date | Nov 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:CURE.X has 20.21 million shares outstanding. The number of shares has decreased by -70.41% in one year.
| Current Share Class | 20.21M |
| Shares Outstanding | 20.21M |
| Shares Change (YoY) | -70.41% |
| Shares Change (QoQ) | +32.57% |
| Owned by Insiders (%) | 19.28% |
| Owned by Institutions (%) | n/a |
| Float | 15.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.38 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.16 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15, with a Debt / Equity ratio of 0.04.
| Current Ratio | 0.15 |
| Quick Ratio | 0.14 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -23.45 |
Financial Efficiency
Return on equity (ROE) is -18.01% and return on invested capital (ROIC) is -9.21%.
| Return on Equity (ROE) | -18.01% |
| Return on Assets (ROA) | -7.49% |
| Return on Invested Capital (ROIC) | -9.21% |
| Return on Capital Employed (ROCE) | -14.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +300.00% in the last 52 weeks. The beta is 4.44, so CSE:CURE.X's price volatility has been higher than the market average.
| Beta (5Y) | 4.44 |
| 52-Week Price Change | +300.00% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 44.75 |
| Average Volume (20 Days) | 13,594 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -240,156 |
| Pretax Income | -284,163 |
| Net Income | -284,163 |
| EBITDA | n/a |
| EBIT | -240,156 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 49,701 in cash and 56,274 in debt, giving a net cash position of -6,573 or -0.00 per share.
| Cash & Cash Equivalents | 49,701 |
| Total Debt | 56,274 |
| Net Cash | -6,573 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 1.60M |
| Book Value Per Share | 0.08 |
| Working Capital | -304,892 |
Cash Flow
| Operating Cash Flow | -77,075 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:CURE.X does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 70.41% |
| Shareholder Yield | 70.41% |
| Earnings Yield | -46.88% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 28, 2024. It was a reverse split with a ratio of 0.1111111.
| Last Split Date | Oct 28, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1111111 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |